Scientific Foundation
The Science Behind ScudoMind
NAI therapy engages five distinct neuropathways simultaneously. This multi-pathway engagement explains both the speed and the breadth of the antidepressant effect observed in clinical evidence.
Key Neuropathways
| Biological Pathway | Key Mechanism & Evidence | Relevance to Antidepressant Effect |
|---|---|---|
| Neuroendocrine Regulation | Attenuates HPA axis hyperactivity by reducing stress-induced corticosterone elevation. | Normalizes the stress response — a core physiological dysfunction in depression. |
| Autonomic Nervous System | Enhances parasympathetic tone (increased HRV) and modulates sympatho-vagal balance via vagal nerve and hypothalamic pathways. | Reduces physiological hyperarousal and promotes somatic recovery and relaxation. |
| Neurotransmitter Modulation | Modulates serotonin (5-HT) levels and accelerates enzymatic oxidation via superoxide pathways. | Modulates monoaminergic signaling systems central to mood regulation. |
| Immunomodulation & Antioxidative | Rebalances Th1/Th2 cytokine profiles, downregulates pro-inflammatory cytokines and Reactive Oxygen Species (ROS) pathways. | Targets the inflammatory hypothesis of depression by reducing neuroinflammation and oxidative stress. |
| Emotional & Cognitive Processing | Increases positive emotional processing, improves vigilance and memory for positive stimuli, and enhances cognitive performance. | Mimics early cognitive shifts seen with conventional antidepressants, reversing negative cognitive bias. |
Results based on multiple small-scale trials including a landmark randomized controlled trial (Goel et al., 2005).
Treatment Comparison
ScudoMind's approach compares favorably to every established alternative on efficacy, tolerability, and cost.
| Treatment | Complexity | Time | Response | Remission | Side Effects | Cost |
|---|---|---|---|---|---|---|
| ScudoMind* | Simple / 1x day · Home/On-the-Go | 5 weeks | 51% | 50% | None | $Low |
| TMS | Clinic · 5×/week | 4–6 wks | ~50% | 31–37% | Mild Headache | $5–13K |
| Cranial Electrical Stimulation | Daily · 2×/day | 8–16 wks | 50–60% | Up to 50% | Very Mild | $3.6K |
| Esketamine | Clinic · 2–1×/week | 4–12 wks | ~50% | 30–50% | Dissociation, Hypertension | $5–18K |
| ECT | Clinic · 3×/week | 6–8 wks | ~54% | 31–47% | Cognitive Memory Loss | $13–25K |
Results based on multiple small-scale trials including a landmark randomized controlled trial (Goel et al., 2005).